Concepedia

Adorján Aszalós

AA

Statistics

Publications

31

Citations

1.1K

H-Index

20

Active since

1968

Affiliations

United States Food and Drug Administration(Current)

University of Debrecen

National Cancer Institute

National Institutes of Health

Cancer Research Center

Adorján Aszalós is an author at United States Food and Drug Administration specializing in medicine, pharmacology, and life sciences.

Publications per year

1968–2008

31

Publications

31

SIRT1 Contributes in Part to Cisplatin Resistance in Cancer Cells by Altering Mitochondrial Metabolism

Xing‐Jie Liang, Toren Finkel, Ding‐Wu Shen et al. · Molecular Cancer Research · 2008 · 120 citations · Full text

, , +17

Fredericamycin A a new antitumor antibiotic. I. Production, isolation and physicochemical properties.

Ramesh C. Pandey, Margaret W. Toussaint, Ronald M. Stroshane et al. · The Journal of Antibiotics · 1981 · 112 citations

, , +7

The effect of ion channel blockers, immunosuppressive agents, and other drugs on the activity of the multi‐drug transporter

James L. Weaver, P. Scott Pine, Adorján Aszalós et al. · International Journal of Cancer · 1993 · 92 citations · Full text

, , +16

Laser scanning and confocal microscopy of daunorubicin, doxorubicin, and rhodamine 123 in multidrug-resistant cells

James L. Weaver, P.Scott Pine, Adorján Aszalós et al. · Experimental Cell Research · 1991 · 79 citations

, , +15

P-glycoprotein, expressed in multidrug resistant cells, is not responsible for alterations in membrane fluidity or membrane potential.

Claudina Alemán, Jean-Philippe Annereau, Xing‐Jie Liang et al. · PubMed · 2003 · 67 citations

, , +11

1–5 of 31